| Evidence-based assessment of current and emerging bladder-sparing therapies for non–muscle-invasive bladder cancer after bacillus Calmette-Guerin therapy: a systematic review … AM Kamat, SP Lerner, M O’Donnell, MV Georgieva, M Yang, BA Inman, ... European urology oncology 3 (3), 318-340, 2020 | 56 | 2020 |
| Comparison of the harms, advantages, and costs associated with alternative guidelines for the evaluation of hematuria MV Georgieva, SB Wheeler, D Erim, R Smith-Bindman, R Loo, C Ng, ... JAMA internal medicine 179 (10), 1352-1362, 2019 | 50 | 2019 |
| Epidemiology and economic burden of Lewy body dementia in the United States U Desai, J Chandler, N Kirson, M Georgieva, HC Cheung, B Westermeyer, ... Current Medical Research and Opinion 38 (7), 1177-1188, 2022 | 41 | 2022 |
| Assessing the impact of open-label designs in patient-reported outcomes: investigation in oncology clinical trials J Lord-Bessen, J Signorovitch, M Yang, M Georgieva, J Roydhouse JNCI Cancer Spectrum 7 (2), pkad002, 2023 | 17 | 2023 |
| Disease progression and longitudinal clinical outcomes of Lewy body dementia in the NACC database J Chandler, M Georgieva, U Desai, N Kirson, H Lane, HC Cheung, ... Neurology and Therapy 12 (1), 177-195, 2023 | 16 | 2023 |
| Health care resource utilization and costs for patients with spinal muscular atrophy: findings from a retrospective US claims database analysis W Toro, M Yang, M Georgieva, W Song, A Patel, A Jiang, A Zhao, ... Advances in Therapy 40 (10), 4589-4605, 2023 | 13 | 2023 |
| Classification, prediction, and concordance of cognitive and functional progression in patients with mild cognitive impairment in the United States: A latent class analysis J Mouchet, KA Betts, MV Georgieva, R Ionescu-Ittu, LM Butler, X Teitsma, ... Journal of Alzheimer’s Disease 82 (4), 1667-1682, 2021 | 10 | 2021 |
| Real-world comparative effectiveness of a third dose of mRNA-1273 versus BNT162b2 among adults aged≥ 65 years in the United States B Kirk, C Bush, A Toyip, KE Mues, E Beck, L Li, SS Laurent, M Georgieva, ... Vaccine 42 (25), 126113, 2024 | 7 | 2024 |
| Real-world effectiveness of a third dose of mRNA-1273 versus BNT162b2 on inpatient and medically attended COVID-19 among immunocompromised US adults T Sun, L Li, KE Mues, MV Georgieva, B Kirk, JA Mansi, N Van de Velde, ... Infectious Diseases and Therapy 13 (8), 1771-1787, 2024 | 7 | 2024 |
| Indirect comparison of the relative vaccine effectiveness of mRNA-1283 vs. BNT162b2 vaccines against symptomatic COVID-19 among US adults E Beck, M Georgieva, WJ Wang, A Gomez-Lievano, H Wang, Y Gao, ... Current medical research and opinion, 1-12, 2025 | 6 | 2025 |
| The impact of progression on healthcare resource utilization and costs among patients with high-grade non-muscle invasive bladder cancer after bacillus Calmette-Guérin therapy … M Yang, MV Georgieva, I Bocharova, M Vembusubramanian, K Qian, ... Advances in Therapy 38 (3), 1584-1600, 2021 | 6 | 2021 |
| Real-world systemic therapy utilization in Medicare patients with locally advanced or metastatic urothelial carcinoma diagnosed between 2008 and 2012 MA Dinan, MV Georgieva, Y Li, T Zhang, M Harrison, R Shenolikar, ... Journal of Geriatric Oncology 12 (2), 298-304, 2021 | 6 | 2021 |
| Impact of differential rates of disease progression in amyloid-positive early Alzheimer’s disease: findings from a longitudinal cohort analysis J Chandler, M Georgieva, U Desai, N Done, A Gomez-Lievano, W Ye, ... The Journal of Prevention of Alzheimer's Disease 11 (2), 320-328, 2024 | 5 | 2024 |
| Potential Implications of Slowing Disease Progression in Amyloid-Positive Early Alzheimer’s Disease: Estimates from Real-World Data J Chandler, N Done, U Desai, M Georgieva, A Gomez-Lievano, W Ye, ... The Journal of Prevention of Alzheimer's Disease 11 (2), 310-319, 2024 | 5 | 2024 |
| Patient and caregiver outcomes after onasemnogene abeparvovec treatment: findings from the cure sma 2021 membership survey W Toro, M Yang, M Georgieva, A Anderson, N LaMarca, A Patel, ... Advances in therapy 40 (12), 5315-5337, 2023 | 5 | 2023 |
| Disease progression among patients who receive available bladder preservation therapies after failure of BCG therapy in the SEER-Medicare data. AM Kamat, MV Georgieva, J Song, I Bocharova, K Qian, A Guo, M Yang Journal of Clinical Oncology 38 (6_suppl), 453-453, 2020 | 5 | 2020 |
| Comparison of the harms, advantages, and costs associated with alternative guidelines for the evaluation of hematuria. JAMA Intern Med. 2019; 179 (10): 1352–62 MV Georgieva, SB Wheeler, D Erim, R Smith-Bindman, R Loo, C Ng, ... | 5 | 2019 |
| Outcomes of single-agent onasemnogene abeparvovec or nusinersen, and of nusinersen switching to onasemnogene abeparvovec, in patients with spinal muscular atrophy: results of a … M Yang, M Georgieva, E Wu, O Dabbous, N LaMarca, L Shenouda, ... Neurology 96 (15_supplement), 2346, 2021 | 4 | 2021 |
| Simulated costs of the ASCO patient-centered oncology payment model in Medicare beneficiaries with newly diagnosed advanced ovarian cancer HA Moss, LJ Havrilesky, FF Wang, MV Georgieva, LH Hendrix, MA Dinan Journal of Oncology Practice 15 (12), e1018-e1027, 2019 | 4 | 2019 |
| CO41 Real-World Outcomes of Nusinersen or Onasemnogene Abeparvovec (OA) Monotherapy, or Switching to OA from Nusinersen in SMA Patients Aged≥ 6 Months O Dabbous, M Yang, M Georgieva, W Toro, N LaMarca, A Patel, ... Value in Health 26 (6), S21-S22, 2023 | 2 | 2023 |
